Kura Oncology, Inc. shareholders approved Approval of our Amended ESPP at the 2026-06-04 meeting.
“Proposal 6. Approval of our Amended ESPP For Against Abstain Broker Non-Votes 58,306,174 213,434 161,424 11,097,548”
Kura Oncology, Inc. — fact timeline
Source-grounded facts extracted from Kura Oncology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kura Oncology, Inc. shareholders approved Approval of our Amended 2014 Plan at the 2026-06-04 meeting.
“Proposal 5. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 48,402,820 10,099,296 178,916 11,097,548”
Kura Oncology, Inc. shareholders approved Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation at the 2026-06-04 meeting.
“Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain Broker Non-Votes 48,362,762 54,055 1,586,672 8,677,543 11,097,548”
Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.
“Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 48,783,834 1,141,854 8,755,344 11,097,548”
Kura Oncology, Inc. shareholders approved Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 69,385,497 140,763 252,320 —”
Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.
“Proposal 1. Election of Directors Name of Director Elected For Withheld Broker Non-Votes Diane Parks 44,060,724 14,620,308 11,097,548”
Kura Oncology, Inc. reported first quarter ended March 31, 2026 results: revenue $5.8 million.
“identified as being incorporated therein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTITM (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching”
Kura Oncology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue Net product revenue: $2.1 million; Collaboration revenue: $15.2 million.
“Fourth Quarter 2025 Financial Results • Net product revenue: $2.1 million (first five weeks of commercial sales following November 13 approval of KOMZIFTI). • Collaboration revenue: $15.2 million, compared to $53.9 million for Q4”
Kura Oncology, Inc.: The Board adopted amended and restated bylaws effective January 28, 2026, making numerous changes to stockholder meeting procedures, advance notice requirements, quorum and voting thresholds, and other governance provisions (effective 2026-01-28).
“On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.”
Stephen Dale resigned as Chief Medical Officer at Kura Oncology, Inc..
“On January 1, 2025 (the “Dale Separation Date”), Stephen Dale, M.D. tendered his resignation from his position as the Chief Medical Officer of Kura Oncology, Inc. (the “Company”), effective as of January 2, 2025, in order to focus on recovery from personal health challenges.”
Michael J. Vasconcelles, M.D. was appointed as Class III Director at Kura Oncology, Inc..
“On September 13, 2024, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael J. Vasconcelles, M.D. as (i) a Class III director of the Company”
Kura Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $49.5 million.
“Kura Oncology, Inc. (the "Company") issued a press release announcing the Company's financial results for the first quarter ended March 31, 2024 and providing a corporate update.”
Kura Oncology, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
“On February 27, 2024, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a corporate update.”
Kura Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-01-26).
“On January 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Warrant Shares held by the Purchasers (the “Registrable Securities”).”
Kura Oncology, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at approximately $150.0 million (effective 2024-01-24).
“On January 24, 2024, Kura Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) (i) an aggregate of 1,376,813 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $17.25 per share, and (ii), in lieu of shares of Common Stock to certain Purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 7,318,886 shares of Common Stock (the “Warrant Shares”) at a purchase price of $17.2499 per Pre-Funded Warrant (representing the $17.25 per Share purchase price less the exercise price of $0.0001 per Warrant Share).”
Kura Oncology, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 2, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023 and providing a corporate update.”
Kura Oncology, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 3, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2023 and providing a corporate update.”
Kura Oncology, Inc. shareholders approved Approval of Amended 2014 Plan at the 2023-05-31 meeting.
“For Against Abstain Broker Non-Votes 46,803,922 5,914,387 1,394,867 1,860,281”
Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-05-31 meeting.
“For Against Abstain Broker Non-Votes 51,834,962 879,497 1,398,717 1,860,281”
Kura Oncology, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
“For Against Abstain Broker Non-Votes 55,916,556 34,565 22,336 —”
Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2023-05-31 meeting.
“Name of Director Elected For Withheld Broker Non-Votes Diane Parks 39,370,803 14,742,373 1,860,281 Mary T. Szela 53,945,761 167,415 1,860,281”
Kura Oncology, Inc. reported first quarter ended March 31, 2023 results: net income $34.1 million.
“Net loss for the first quarter of 2023 was $34.1 million”
Kura Oncology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“On February 23, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.”
Kirsten Flowers resigned as Chief Commercial Officer at Kura Oncology, Inc..
“On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Commercial Officer, effective as of January 27, 2023 (the “Separation Date”), in order to pursue other opportunities.”
Kura Oncology, Inc. incurred term loan of up to $125.0 million with Hercules Capital, Inc. at the greater of (i) the prime rate as reported in The Wall Street Journal minus 6 maturing the fifth anniversary of the Effective Date.
“the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date, (ii) two additional tranches of term loans in the amounts of up to $35.0 million (the “Tranche 2 Loan”) and $40.0 million (the “Tranche 3 Loan”), respectively, which will become available to the Company upon the Company’s satisfaction of certain terms and conditions set forth in the Loan Agreement, and (iii) a final tranche of term”
Kura Oncology, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at Up to $125.0 million in senior secured term loans, with initial $10.0 million funded immediately aft (effective 2022-11-02).
“Also on November 2, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date”
Kura Oncology, Inc. entered into Securities Purchase Agreement with Bristol-Myers Squibb Company valued at 1,370,171 shares of common stock at $18.2459 per share for gross proceeds of approximately $25.0 mil (effective 2022-11-02).
“On November 2, 2022, Kura Oncology, Inc. (“Kura” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Bristol-Myers Squibb Company (“BMS”).”
Kura Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022 and providing a corporate update.”
Troy E. Wilson was appointed as Principal Financial Officer at Kura Oncology, Inc..
“On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.”
Thomas Doyle was appointed as Senior Vice President, Finance and Accounting, Principal Accounting Officer at Kura Oncology, Inc..
“On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.”
Marc Grasso resigned as Chief Financial Officer at Kura Oncology, Inc..
“On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.”
Helen Collins, M.D. was appointed as Class II director at Kura Oncology, Inc..
“appointed Helen Collins, M.D. as a Class II director of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.